We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

Vibostolimab was part of a promising new category of immunotherapies known as anti-TIGIT. This type of drug binds to TIGIT ...

US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...

Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programmes for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...